Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
TryptamineLSD, psilocybin, mescaline +5 moreLSD, psilocybin, mescaline, DMT, AL-LAD, 1P-LSD, 1B-LSD, 1CP-LSD show less
1P-ETH-LAD
1-propanoyl-6-ethyl-6-nor-lysergic acid diethylamide
1P-ETH-LAD (1-propionyl-N⁶-ethyl-6-norlysergic acid diethylamide) is a synthetic psychedelic of the lysergamide class. It is a prodrug of ETH-LAD, a close structural relative of LSD. It activates serotonin receptors in the brain, producing the visual and cognitive distortions characteristic of classical psychedelics.
1P-ETH-LAD (1-propionyl-N⁶-ethyl-6-norlysergic acid diethylamide) is a semi-synthetic psychedelic of the lysergamide class. It is a prodrug of ETH-LAD, a close structural relative of LSD. After conversion to its active form, 1P-ETH-LAD acts as a 5-HT₂A receptor partial agonist, producing its effects by disrupting serotonergic filtering of sensory and cognitive input.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
TryptamineLSD, psilocybin, mescaline +5 moreLSD, psilocybin, mescaline, DMT, AL-LAD, 1P-LSD, 1B-LSD, 1CP-LSD show less
ETH-LAD, the active compound, was first synthesized in 1976 by Japanese researchers; 1P-ETH-LAD — the prodrug form — appeared on the research chemical market between 2015 and 2017. It was engineered to sidestep controlled substance laws targeting LSD-related compounds, and first scientifically characterized in 2017.[1] It remains unscheduled in most countries and circulates in small quantities among research chemical users.
Subjective effects include geometric visual patterns, color enhancement, time alteration, and sharp analytical thinking. The experience is cerebral and visually intense — colder and more analytical than LSD, with less emotional warmth. Nausea during onset, thought loops, and anxious fixation are common unwanted effects.
1P-ETH-LAD does not produce physical dependence, and tolerance builds so rapidly after a single dose that compulsive redosing becomes self-limiting.[2] The dominant risk is psychological — difficult experiences scale with dose, and a rare but documented condition of lasting visual disturbances can follow even a single use. No clinical trials or formal toxicity studies have been published; current understanding rests on laboratory data, structural analogy to LSD,[3] and user reports.
History[edit]
Discovery
ETH-LAD, the active compound, was first synthesized in 1976 by Japanese researchers investigating microbial degradation of LSD. Hoffman and Nichols later confirmed it as a potent LSD-like hallucinogen capable of substituting for LSD in animal studies.[4] 1P-ETH-LAD — the prodrug form — did not exist until the designer lysergamide era of the mid-2010s.
Market emergence
1P-ETH-LAD appeared on the research chemical market between 2015 and 2017, engineered to circumvent controlled substance laws. In 2017, Brandt and colleagues confirmed its identity and its conversion to ETH-LAD.[1] That study also established that 1P-ETH-LAD shares a molecular formula with 1B-LSD — the atoms are simply arranged differently.[5]
Forensic detection
ETH-LAD was detected in blotter products in Japan between 2014 and 2017.[6] Standard drug panels do not detect 1P-ETH-LAD or its metabolites; specialized methods such as LC-MS/MS are required.[7]
The name "1P-ETH-LAD" follows the systematic naming convention of the designer lysergamide series: "1P" marks a propionyl group at the indole nitrogen, while "ETH-LAD" names the active metabolite. This pattern — shared with 1P-LSD, 1cP-LSD, and 1B-LSD — signals the prodrug structure and intended active compound to experienced research chemical users. The earlier "Return of the Lysergamides" installments[8][9] helped establish the 1-acyl lysergamide class as a recognized category in the novel psychoactive substance landscape.
Chemistry[edit]
1P-ETH-LAD belongs to the 1-acyl lysergamide family, alongside 1P-LSD, ALD-52, and 1B-LSD. Two structural features distinguish it from LSD: an ethyl group at one nitrogen and a propionyl group at another.[1] That propionyl group makes 1P-ETH-LAD pharmacologically inert — it must first be converted to its active form, ETH-LAD, in the body. Its molecular formula is C₂₄H₃₁N₃O₂ — identical to 1B-LSD, though the atoms are distributed differently.[5]
Only one mirror-image arrangement of the molecule at its two chirality centers produces psychedelic effects — the opposite form is inactive, as with all lysergamides. No published data on melting point or solubility exist for 1P-ETH-LAD. Like all lysergamides, it is sensitive to light, heat, and oxidation; cool, dark, sealed storage is standard practice.[10]
Pharmacology[edit]
Prodrug conversion
1P-ETH-LAD is a prodrug — the body strips away the propionyl group, releasing its active form, ETH-LAD. This conversion was confirmed in lab studies using human blood at body temperature.[1] A closely related compound, 1P-LSD, undergoes near-complete conversion after swallowing, with essentially all of the dose reaching the brain as the active form.[11]
Mechanism of action
ETH-LAD works primarily by activating serotonin receptors in the brain.[12][2] It also binds dopamine receptors strongly[4] — more than most classical psychedelics — adding a stimulant and analytical edge through interactions between serotonin and dopamine receptor systems.[13]
Pharmacokinetics
No human timing data exist for 1P-ETH-LAD. Based on 1P-LSD, the active compound has an half-life of roughly 6 hours.[11] Community reports place onset at 30–90 minutes, peak at 2–4 hours, and total duration at 6–12 hours. The compound and its metabolites typically do not appear on standard drug tests.[7]
Neuroscience[edit]
Where it acts
No brain imaging or electrophysiology data exist for 1P-ETH-LAD or ETH-LAD — all neural descriptions are extrapolated from other serotonergic psychedelics. ETH-LAD is expected to disrupt the default mode network — the brain's self-referential processing hub — loosening the sense of self. Serotonin receptor activation also reduces the brain's filtering of incoming sensory information, flooding awareness with unfiltered perception.
Why it matters
ETH-LAD's strong dopamine receptor engagement[13] distinguishes it from pure tryptamine psychedelics and likely contributes to its stimulant, analytical quality. Like other serotonin-activating psychedelics, it is expected to promote rapid structural changes in cortical neurons — a form of neuroplasticity — though this has not been directly tested for ETH-LAD.
The N⁶-ethyl modification changes how ETH-LAD binds to its targets — whether this alters neuroplasticity engagement compared to LSD remains untested. Genetic variation in drug-metabolizing enzymes also introduces unpredictability: the same variation that causes roughly 75% higher LSD exposure in some individuals[14] likely affects ETH-LAD too, meaning the same 1P-ETH-LAD dose may produce substantially different experiences in different people.
Subjective Effects[edit]
1P-ETH-LAD produces a cerebral, visually driven psychedelic state. Colors sharpen, geometry emerge, and thinking takes on an analytical, introspective quality. The overall tone is cool and precise — lucid in a way that can feel crystalline or, in difficult moments, alienating. Emotional warmth is present but muted.
The closest comparison is ETH-LAD, from which 1P-ETH-LAD is pharmacologically indistinguishable after conversion in the body. Compared to LSD, visual intensity is higher per dose while emotional resonance is lower — placing this compound toward the purely perceptual-cognitive end of the lysergamide spectrum.
1P-ETH-LAD appeared on the research chemical market in the mid-2010s as part of a wave of designer lysergamides engineered to sidestep controlled substance scheduling. Its first scientific characterization came in 2017, when analysts confirmed its identity and demonstrated prodrug conversion to ETH-LAD in human serum.[1] It remains unscheduled in most jurisdictions and circulates in small quantities among research chemical users.
Subjective effects include geometric visual patterns, color enhancement, analytical introspection, and time alteration. The experience is described as cerebral and visually intense — a colder, more analytical psychedelic state with less emotional warmth than LSD. Nausea during onset, thought loops, and anxious fixation are common unsought effects.
1P-ETH-LAD produces no physical dependence, and rapid tolerance after a single dose makes compulsive redosing self-limiting.[2] The primary risk is psychological: challenging experiences scale with dose, predisposition, and setting, with a class-level risk of HPPD. No clinical trials, case reports, or formal toxicity studies have been published for either compound — the current understanding rests on in vitro data, structural analogy to LSD,[3] and community reports.
History[edit]
Discovery
The pharmacological lineage of 1P-ETH-LAD traces to its active metabolite, ETH-LAD, first synthesized in 1976 by Japanese researchers investigating microbial degradation of LSD. Nearly a decade later, Hoffman and Nichols published a definitive structure–activity study confirming ETH-LAD as a potent LSD-like hallucinogen capable of substituting for LSD in animal discrimination assays.[4] 1P-ETH-LAD itself — the propionyl-protected prodrug form — did not exist until the designer lysergamide era of the mid-2010s.
Market emergence
1P-ETH-LAD appeared on the research chemical market between approximately 2015 and 2017, part of a broader wave of 1-acyl lysergamides engineered to circumvent controlled substance laws. Its first scientific characterization was published in 2017 by Brandt and colleagues as Part III of the "Return of the Lysergamides" series, which confirmed the compound's identity and its prodrug conversion to ETH-LAD.[1] That study also established that 1P-ETH-LAD is a constitutional isomer of 1B-LSD — both share the molecular formula C₂₄H₃₁N₃O₂ but distribute the atoms differently.[5]
Forensic detection
ETH-LAD itself was identified in blotter products in Japan between 2014 and 2017 through GC-MS and LC-MS analysis.[6] Standard immunoassay drug panels do not detect 1P-ETH-LAD or its metabolites; identification requires targeted analytical methods such as LC-MS/MS.[7] Cayman Chemical catalogued the compound as an analytical reference standard.[8]
The name "1P-ETH-LAD" follows the systematic naming convention of the designer lysergamide series: "1P" denotes a propionyl group at the indole nitrogen (position 1), while "ETH-LAD" identifies the active metabolite, N⁶-ethyl-6-norlysergic acid diethylamide. This naming pattern — shared with 1P-LSD, 1cP-LSD, and 1B-LSD — functions as a chemical shorthand that signals both the prodrug modification and the intended active compound to experienced research chemical users. The earlier installments of the "Return of the Lysergamides" series[9][10] helped establish the 1-acyl lysergamide class as a recognized category within the novel psychoactive substance landscape.
Chemistry[edit]
Structural class
1P-ETH-LAD belongs to the 1-acyl lysergamide subgroup of indole alkaloids, alongside 1P-LSD, ALD-52, 1cP-LSD, and 1B-LSD. The core structure is the tetracyclic ergoline ring system shared by all lysergic acid derivatives. Two modifications distinguish 1P-ETH-LAD from LSD: an ethyl group at the N⁶ nitrogen (replacing LSD's methyl) and a propionyl group at the indole N-1 position.[1]
The N-1 propionyl group renders the compound pharmacologically inert at serotonin and dopamine receptors until hydrolysis releases the active metabolite ETH-LAD. 1P-ETH-LAD is a constitutional isomer of 1B-LSD: both share the molecular formula C₂₄H₃₁N₃O₂, but the extra atoms beyond the LSD core are arranged differently — a three-carbon propionyl chain at N-1 plus an ethyl at N⁶ in 1P-ETH-LAD versus a four-carbon butanoyl at N-1 with the standard N-methyl in 1B-LSD.[5]
Molecular properties
| Molecular formula | C₂₄H₃₁N₃O₂ |
| Molecular weight | 393.5 g/mol |
Key functional groups include the N,N-diethylcarboxamide at C-9 (the amide pharmacophore required for serotonergic activity), the N⁶-ethyl substituent on the piperidine nitrogen, and the N-1 propionyl group that confers prodrug character.[1]
Stereochemistry
Like all pharmacologically active lysergamides, 1P-ETH-LAD requires the (6aR,9R) absolute configuration at the two chirality centers within the ergoline ring. The opposite enantiomer — the (6aS,9S) or iso-lysergamide configuration — is pharmacologically inactive. This stereochemical requirement is universal across the lysergamide class.
Physical properties
No published data on melting point, solubility, or crystalline form exist for 1P-ETH-LAD. By analogy with other 1-acyl lysergamides, the compound is expected to be a white to off-white solid, soluble in polar organic solvents and sparingly soluble in water. Lysergamides are generally sensitive to light, heat, and oxidation; storage at low temperature under inert atmosphere is standard practice.[8]
Pharmacology[edit]
Prodrug conversion
1P-ETH-LAD functions as a prodrug for ETH-LAD. The N-1 propionyl group is cleaved under physiological conditions, releasing the active compound. In vitro studies confirmed conversion to ETH-LAD in human serum at 37°C, though the parent compound remained detectable at 24 hours, indicating incomplete hydrolysis under those conditions.[1]
The closest pharmacokinetic parallel is 1P-LSD, where oral administration yielded only LSD in serum and urine — the parent prodrug was undetectable — with effective bioavailability of the active form approaching 100%.[11] By analogy, oral 1P-ETH-LAD likely undergoes near-complete conversion to ETH-LAD during first-pass metabolism, though this has not been confirmed in humans.
The 1-acyl substitution itself substantially reduces receptor binding. Across a range of 1-acyl LSD derivatives, the acyl group lowers binding affinity at serotonin and dopamine receptors by one to two orders of magnitude compared to the parent lysergamide.[12] 1P-ETH-LAD is therefore pharmacologically inert until hydrolysis occurs.
Mechanism of action
The principal psychedelic action of ETH-LAD — and by extension 1P-ETH-LAD after prodrug conversion — is 5-HT₂A receptor partial agonism.[13][2] The psychedelic behavioral effects are driven primarily through Gq-coupled signaling rather than β-arrestin2 recruitment.[2][14]
ETH-LAD binds strongly to both 5-HT₂A and dopamine D2 receptors,[4]safety citation needed with additional activity at 5-HT₁A and 5-HT₂C. The 5-HT₁A component may modulate the psychedelic response — in a related lysergamide (LSM-775), 5-HT₁A activation attenuated 5-HT₂A-mediated behavioral effects.[15]
The dopaminergic activity contributes stimulant and cognitive dimensions to the experience. LSD-class compounds enhance signaling through D2–5-HT₂A heteroreceptor complexes, where activation of the 5-HT₂A protomer allosterically modulates the D2 protomer.[16] ETH-LAD's N⁶-ethyl substitution preserves LSD-like behavioral properties in animal assays.[4]
Metabolism
In vitro studies using human liver preparations identified the primary metabolic pathways as N-dealkylation and hydroxylation, with deacylation to ETH-LAD also observed.[7] Parent drug and metabolites were not detectable in rat urine at expected recreational-equivalent doses, highlighting the analytical challenge these compounds pose for routine drug screening.[7]
For the closely related LSD, genetic variation in drug-metabolizing enzymes significantly influences the experience — individuals with certain enzyme variants show approximately 75% higher drug exposure and prolonged effects.[17] Similar variation is plausible for ETH-LAD but has not been studied.
Pharmacokinetics
No human pharmacokinetic data exist for 1P-ETH-LAD or ETH-LAD. All temporal parameters are inferred from prodrug structural analog data and community reports.
The best available proxy is the pharmacokinetic study of 1P-LSD: oral 1P-LSD (100 µg) yielded an active metabolite half-life of approximately 6.4 hours.[11] Oral bioavailability of LSD approaches 80%,[18] while the 1-acyl prodrug form may paradoxically enhance systemic delivery, with effective bioavailability approaching 100%.[11]
Community-reported timing for 1P-ETH-LAD includes onset at 30–90 minutes, peak at 2–4 hours, and total duration of 6–12 hours. The Global Drug Survey 2016 found a modal total duration of 8 hours for LSD analogue users.[19] The slightly delayed onset compared to ETH-LAD is consistent with the additional time required for prodrug hydrolysis.
Neuroscience[edit]
Where it acts
No direct neuroimaging or electrophysiological data exist for 1P-ETH-LAD or ETH-LAD. All neural mechanism descriptions are extrapolated from the serotonergic psychedelic class. As a serotonin 2A receptor agonist, ETH-LAD is expected to disrupt default mode network integrity — the brain's self-referential processing hub — producing the characteristic loosening of ego boundaries.
Simultaneously, 5-HT₂A activation on thalamic and cortical neurons reduces the brain's filtering of sensory input, flooding awareness with perceptual information. ETH-LAD's strong dopamine D2 engagement adds a dopaminergic dimension absent from pure tryptamine psychedelics, potentially producing unique downstream effects through D2–5-HT₂A heteroreceptor complexes.[16]
Why it matters
The REBUS (Relaxed Beliefs Under Psychedelics) model offers the most explanatory framework: psychedelics relax the precision of the brain's top-down predictions, allowing raw sensory signals greater influence on conscious experience. This accounts for the intensified perception, loosened associations, and destabilized self-models characteristic of the psychedelic state.
ETH-LAD, like other 5-HT₂A agonists, is also expected to function as a psychoplastogen — promoting rapid structural changes in cortical neurons through plasticity signaling pathways. Whether ETH-LAD drives equivalent neuroplasticity to LSD remains untested.
Several questions remain unresolved. The N⁶-ethyl modification changes receptor binding kinetics — does this alter neuroplasticity engagement compared to LSD? ETH-LAD's nearly equipotent binding at D2 and 5-HT₂A differs from LSD's slightly serotonin-preferring profile — does this translate to a measurably different neural activation pattern?
Subjective Effects[edit]
The 1P-ETH-LAD experience occupies a distinctive position within the lysergamide family: prominently visual and analytically sharp, with a cerebral quality that users frequently describe as "colder" than LSD. Set and setting exert decisive influence, with psychological context, social environment, and prior psychedelic history shaping both the character and emotional tone of the experience. At lower doses the effect is primarily perceptual — pattern recognition enhancement, color saturation, and geometric complexity — while higher doses bring deeper cognitive disruption and ego destabilization.
The closest experiential structural analog is ETH-LAD itself, from which 1P-ETH-LAD is pharmacologically indistinguishable after prodrug conversion. Compared to LSD, the experience delivers higher visual intensity per microgram with less empathogenic warmth, placing it closer to a pure perceptual-cognitive psychedelic. The prodrug onset is somewhat slower and more gradual than direct ETH-LAD administration.
Effect Grid
A full psychedelic experience — prominent geometry, color alteration, object transformations, and visual drifting dominate the visual field. Symmetrical texture repetition and visual diffraction may appear. Music enhancement is notable. The headspace is analytical and introspective, with less emotional warmth than LSD at comparable intensity.
Body load is moderate: nausea is common during the come-up, temperature dysregulation and vasoconstriction are frequently reported, and spontaneous body sensations may occur throughout. Stimulation and wakefulness are pronounced. Pupil dilation is reliable.
Set and setting are critically important at this level. The experience commits the user for 8–12 hours. Sleep is impossible for at least 8 hours. ETH-LAD is reported as more visually intense per microgram than LSD.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Music enhancement · Tracers · After-images · Environmental patterning · Visual breathing · Visual morphing · Depth perception distortion · Symmetrical texture repetition · Auditory enhancement · Brightness alteration · Light sensitivity · Peripheral vision distortion · Perspective distortion · Sound sensitivity · Touch enhancement · Holotropic state · Visual diffraction · Auditory distortion · Auditory misinterpretation · Proprioceptive distortion · Vestibular distortion · Visual melting · Visual acuity enhancement · Peripheral misidentification · Spatial disorientation · Synesthesia · Visual haze / noise · Flashbacks · Object transformations · Environmental orbism / cubism · Object activation · Internal hallucinations · Visual scenery slicing · External hallucinations · Visual recursion · Perspective hallucinations · Auditory hallucinations · Persisting hallucinations
Visual breathing · Visual morphing · Depth perception distortion · Symmetrical texture repetition · Auditory enhancement · Brightness alteration · Light sensitivity · Peripheral vision distortion · Perspective distortion · Sound sensitivity · Touch enhancement · Holotropic state · Visual diffraction · Auditory distortion · Auditory misinterpretation · Proprioceptive distortion · Vestibular distortion · Visual melting · Visual acuity enhancement · Peripheral misidentification · Spatial disorientation · Synesthesia · Visual haze / noise · Flashbacks · Object transformations · Environmental orbism / cubism · Object activation · Internal hallucinations · Visual scenery slicing · External hallucinations · Visual recursion · Perspective hallucinations · Auditory hallucinations · Persisting hallucinations
Body high · Insomnia · Appetite suppression · Spontaneous body sensations · Laughter fits · Heart rate perception changes · Nausea · Bodily lightness · Body schema distortion · Muscle tension · Restlessness · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Temperature dysregulation · Dizziness · Motor control impairment · Nystagmus (eye wobbles) · Bruxism · Bodily pressures · Breathing alteration · Dry mouth · Excessive sweating · Headache · Trembling · Bodily heaviness · Involuntary body movements · Vomiting · Motor control enhancement · Bodily dissociation · Tactile hallucination
Spontaneous body sensations · Laughter fits · Heart rate perception changes · Nausea · Bodily lightness · Body schema distortion · Muscle tension · Restlessness · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Dizziness · Motor control impairment · Nystagmus (eye wobbles) · Bruxism · Bodily pressures · Breathing alteration · Dry mouth · Excessive sweating · Headache · Trembling · Bodily heaviness · Involuntary body movements · Vomiting · Motor control enhancement · Bodily dissociation · Tactile hallucination
Immersion enhancement · Novelty enhancement · Introspection enhancement · Thought connectivity · Thought acceleration · Cognitive euphoria · Cognitive flexibility · Multiple thought streams · Creativity enhancement · Thought loops · Increased nature relatedness · Synchronicity · Analysis enhancement · Humor enhancement · Memory suppression · Cognitive fatigue · Cognitive impairment · Focus suppression · Thought disorganization · Motivation enhancement · Information processing enhancement · Cognitive dysphoria · Confusion · Information processing suppression · Memory fragmentation · Focus enhancement · Delusions of sobriety · Language suppression · Memory replays · Delusions
Thought connectivity · Thought acceleration · Cognitive euphoria · Cognitive flexibility · Multiple thought streams · Creativity enhancement · Thought loops · Increased nature relatedness · Synchronicity · Analysis enhancement · Humor enhancement · Memory suppression · Cognitive fatigue · Cognitive impairment · Focus suppression · Thought disorganization · Motivation enhancement · Information processing enhancement · Cognitive dysphoria · Confusion · Information processing suppression · Memory fragmentation · Focus enhancement · Language suppression · Memory replays · Delusions
Anxiety · Empathy enhancement · Catharsis · Dysphoria · Anxiety suppression · Irritability
Anxiety suppression · Irritability
Social connection · Trust enhancement · Sociability enhancement · Communication enhancement · Flow state · Communication suppression · Ego inflation · Sociability suppression · Social disconnection · Boundary dissolution · Identity alteration · Cognitive disconnection · Ego dissolution
Flow state · Communication suppression · Ego inflation · Sociability suppression · Social disconnection · Boundary dissolution · Identity alteration · Cognitive disconnection · Ego dissolution
Time cessation
Death-rebirth sequence · Entity contact · Transpersonal memory access · Transpersonal visions
Mindfulness enhancement · Recursive awareness
Timeline
Initial awareness of altered state; mild stimulation and body sensations as prodrug hydrolysis begins. Slower onset than direct ETH-LAD due to the additional hydrolysis step.
Rapid escalation of visual and cognitive effects. Nausea is most likely during this phase. Anxiety and anticipation are common as intensity builds.
Full expression of visual distortions, analytical headspace, and time alteration. Maximum intensity across all effect domains. Geometry and color alteration are most prominent.
Gradual reduction in visual intensity. Cognitive effects may persist; body load diminishes. Emotional processing and introspection may occur as perceptual effects recede.
Residual cognitive openness, mild visual sensitivity, and potential fatigue or stimulation. Sleep may remain difficult for several hours.
⚠ Do not drive or operate heavy machinery for at least 12 hours after ingestion, or longer if residual effects persist.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose data exist for 1P-ETH-LAD or ETH-LAD in any species. No controlled toxicity studies, organ assessments, or human fatalities attributed solely to either compound appear in the published literature.
Acute toxicity
The LSD family is considered physiologically non-toxic at recreational doses in healthy individuals.[3] LSD's lethal dose in animals is many times higher than any recreational human dose. Whether that safety margin extends equally to ETH-LAD is unknown. inferred
Heart and circulation
No cardiovascular data exist for 1P-ETH-LAD or ETH-LAD. By class analogy, modest increases in heart rate and blood pressure are expected.[15][16] These are clinically insignificant in healthy people but may matter for those with pre-existing heart conditions. inferred
Psychological Risks
Anxiety, panic, and paranoia are class-level risks for all serotonin-activating psychedelics.[3] Risk increases with personal or family history of psychotic illness, unstable setting, or concurrent substance use. A study of 130,152 people found no elevated mental health problems from lifetime psychedelic use in non-psychotic populations.[17]
Hallucinogen persisting perception disorder (HPPD)
HPPD is a rare but recognized complication of LSD-class psychedelic use.[18] Type 1 involves brief flashback episodes; Type 2 produces chronic perceptual disturbances lasting months to years.[19] It can occur after even a single exposure,[20] and flashback phenomena have been documented in healthy participants in controlled LSD studies.[21]
Treatment options are limited — clonidine, clonazepam, and levetiracetam have shown benefit; risperidone may worsen symptoms.[22] No HPPD cases specifically attributed to 1P-ETH-LAD have been published, but the class-level risk applies.
Tolerance and Dependence
Tolerance develops almost immediately after a dose, through serotonin downregulation.[2] Community estimates suggest it halves in roughly 3 days and fully resets within 7. Cross-tolerance extends to all classical serotonergic psychedelics — LSD, psilocybin, mescaline, DMT, and structural analogs — through the same shared mechanism.[2]
Dependence liability is negligible. A study of 130,152 people found no association between psychedelic use and substance use disorders.[17] No physical withdrawal has been documented for any LSD-class compound.
Drug Interactions
Serotonergic agents
Combining 1P-ETH-LAD with serotonergic drugs risks serotonin syndrome — a potentially life-threatening state of high body temperature, rapid heart rate, muscle rigidity, and confusion.
Tramadol (dangerous): tramadol blocks serotonin reuptake,[23] directly compounding the serotonin-activating effect of ETH-LAD. Serotonin syndrome from tramadol combined with serotonergic agents is well documented.[24] safety citation needed
MAOIs (recommended classification: dangerous): MAOIs block serotonin breakdown, dramatically amplifying psychedelic effects and raising the risk of dangerous serotonin overload. This is a class-level contraindication. safety citation needed
SSRIs/SNRIs: chronic use may reduce psychedelic effects through receptor downregulation; acute co-administration could increase serotonin toxicity risk. safety citation needed
Lithium
Lithium (recommended classification: dangerous): combining lithium with LSD-class psychedelics carries well-documented risk of seizures. This is an absolute contraindication. safety citation needed
Cannabis
Cannabis (classified: unknown): community reports suggest cannabis amplifies psychedelic effects and may increase anxiety, paranoia, and difficult experiences. No controlled data exist.
Contraindications
7 knownAll contraindications are class-inferred from the serotonergic psychedelic literature, not substance-specific. inferred
Absolute contraindications:
- Personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar I with psychotic features): serotonin receptor activation may trigger or worsen psychotic episodes.
- Concurrent lithium use: seizure risk.
- Concurrent MAOI use: serotonin syndrome risk.
Relative contraindications:
- Anxiety disorders: increased risk of acute distress and panic attacks.
- Heart conditions: sympathomimetic effects may be clinically significant.
- Pregnancy: no reproductive toxicity data exist; class-level precaution applies.
- Concurrent serotonergic medications (SSRIs, SNRIs, tramadol, triptans): variable risk from blunted effects to serotonin syndrome.
Harm Reduction[edit]
Forms & Identification
For lysergamide blotters, the critical question is compound identity — blotter can carry any substance, and lysergamides have no distinguishing taste, smell, or appearance.
Ehrlich reagent testing confirms the presence of an indole compound. A purple color reaction rules out the most dangerous substitutions — especially NBOMe compounds, which are active on blotter at similar quantities and carry serious overdose risk — but does not confirm the material is 1P-ETH-LAD specifically. For liquid preparations, volumetric dosing is the only reliable method at microgram-level quantities.
Guidelines
- Test the material. Use Ehrlich reagent at minimum. A purple reaction confirms an indole compound and rules out the most dangerous substitutions.
- Start low. Individual sensitivity to lysergamides varies. Begin at the lower end of the reported range before considering higher doses in future sessions.
- Clear the full day. Effects last 6–12 hours with residual stimulation potentially extending beyond. Arrange transport in advance — do not drive.
- Arrange a sober companion. A trusted person who can provide reassurance and practical support if the experience becomes difficult.
- Eat and hydrate beforehand. A light meal 2–3 hours before reduces nausea risk. Keep water accessible throughout.
- Do not redose. Tolerance builds within the first hour. Redosing extends duration unpredictably without reliably intensifying effects.
- Prepare for intensity. Have a quiet, comfortable fallback space available. Changing environment — a different room, going outside, changing music — can shift a difficult experience.
Set & Setting
Aftercare & integration. The days after a psychedelic experience are a period of heightened psychological openness. Allow time for rest and reflection before returning to demanding responsibilities. Journaling, conversation, or creative expression can help process the experience.
Difficulty sleeping on the night of use is common due to residual stimulation and typically resolves within 24 hours. If disturbing perceptual changes, anxiety, or depersonalization persist beyond a few days, consult a mental health professional — ideally one with experience in psychedelic integration.
Psychedelic experiences are shaped profoundly by mental state (set) and physical environment (setting). A calm, familiar, private space with a trusted companion present provides the strongest foundation. Avoid use during emotional distress or unresolved conflict. First-time users should plan for a full day with no obligations — the duration is long.
Recovery & Support
1P-ETH-LAD does not produce physical dependence or withdrawal. But patterns of frequent use — even without physiological compulsion — can reflect psychological avoidance. If psychedelic use is displacing responsibilities, relationships, or emotional processing, professional support may be warranted.
Resources include the Fireside Project (psychedelic peer support line), MAPS integration resources, and local harm reduction organizations. For broader substance use concerns, SAMHSA's National Helpline (1-800-662-4357) provides free referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult psychedelic experiences are uncomfortable but not medically dangerous. Seek emergency help immediately if the person expresses intent to harm themselves or others, loses all contact with reality, shows signs of seizure, or develops dangerously high body temperature.
Immediate steps:
- Stay with the person. Speak calmly and simply.
- Remove hazards from the environment — sharp objects, access to heights, vehicle keys.
- Guide them to a quiet, low-stimulation space if conscious and cooperative.
- If unconscious, place in the recovery position and call emergency services immediately.
- Call emergency services if there is any risk of self-harm, seizure, or loss of consciousness.
What to tell the dispatcher: Name the substance (1P-ETH-LAD or "an LSD-like research chemical"), estimated dose, time of ingestion, and current symptoms. Good Samaritan laws protect callers in many jurisdictions.
Legal Status[edit]
The legal status of 1P-ETH-LAD depends on whether its active metabolite ETH-LAD is specifically controlled in a given country, and whether blanket novel psychoactive substance laws apply. Neither compound is controlled under any international treaty.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | ETH-LAD: Class A / Schedule 1 (Misuse of Drugs Act 1971). 1P-ETH-LAD: covered by Psychoactive Substances Act 2016. | ETH-LAD controlled from 7 January 2015 alongside ALD-52, AL-LAD, PRO-LAD, and LSZ.[25] 1P-ETH-LAD is not a named controlled substance but is illegal to produce, supply, or import under the Psychoactive Substances Act 2016.[26] |
| Germany | Controlled under NpSG (Neue-psychoaktive-Stoffe-Gesetz) | Effective 18 July 2019. Production, import with intent to market, administration to others, and trading are criminal offences. Possession is illegal but not penalized under NpSG. |
| United States | Not specifically scheduled | Neither ETH-LAD nor 1P-ETH-LAD is listed in the Controlled Substances Act. The Federal Analogue Act (21 U.S.C. § 813) may apply when intended for human consumption, treating the compound as Schedule I by analogy to LSD. Legal status remains ambiguous. |
| Canada | Not confirmed as controlled | No specific scheduling identified as of 2025. Status requires verification against current CDSA schedules. citation needed |
| Australia | Not confirmed | Specific scheduling under the Poisons Standard not verified. Analogous treatment to 1P-LSD is plausible but unconfirmed. citation needed |
| Japan | ETH-LAD under evaluation; 1P-ETH-LAD status unconfirmed | ETH-LAD detected in paper products 2014–2017.[6] 1P-LSD designated as controlled from April 2016. Current status of 1P-ETH-LAD not confirmed. |
Analog and prodrug considerations
The prodrug nature of 1P-ETH-LAD creates a distinctive legal dynamic. In jurisdictions where ETH-LAD is controlled (such as the UK), 1P-ETH-LAD may fall under separate blanket legislation. In jurisdictions using structural analog laws (such as the US Federal Analogue Act), legal exposure depends on whether 1P-ETH-LAD is deemed substantially similar to LSD and intended for human consumption. This has not been resolved by case law for 1P-ETH-LAD specifically.
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify current status before drawing conclusions.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose data exist for 1P-ETH-LAD or ETH-LAD in any species. No controlled toxicity studies, organ assessments, or therapeutic index calculations have been published. No human fatalities attributed solely to either compound appear in the published literature.
Acute toxicity
By structural class analogy, the LSD family is regarded as physiologically non-toxic at recreational doses in otherwise healthy individuals.[3] LSD's lethal dose in animals is several orders of magnitude above recreational human doses. Whether this safety margin extends equivalently to ETH-LAD is unknown. inferred
Heart and circulation
No direct cardiovascular data exist for 1P-ETH-LAD or ETH-LAD. By class analogy, LSD produces modest increases in heart rate and blood pressure.[20] These changes are clinically insignificant in healthy people but may matter for those with pre-existing heart conditions.
Serotonergic psychedelics commonly produce sympathomimetic effects including increased heart rate and blood pressure.[21]
inferred All physical safety claims for 1P-ETH-LAD rest on structural class inference from the LSD family, not substance-specific evidence.
Psychological Risks
Acute psychological distress — anxiety, panic, paranoia, and challenging experiences — is a class-level risk for all serotonin 2A receptor agonist psychedelics.[3] Risk increases with personal or family history of psychotic illness, anxiety disorders, uncontrolled setting, and concurrent substance use. Population-level data from 130,152 individuals found no association between lifetime psychedelic use and increased mental health problems in non-psychotic populations.[22]
Hallucinogen persisting perception disorder (HPPD)
HPPD is a recognized but rare complication of LSD-class psychedelic use. Two subtypes exist: Type 1 (brief, self-limiting flashback episodes) and Type 2 (chronic perceptual disturbances that may persist for months to years).[23] HPPD can occur after even a single exposure,[24] and LSD is among the most commonly implicated substances.[25]
Controlled LSD studies have documented flashback phenomena in healthy participants.[26] Treatment options are limited — clonidine, clonazepam, and levetiracetam have shown benefit, while risperidone may worsen symptoms.[27] No HPPD cases specifically attributed to 1P-ETH-LAD or ETH-LAD have been published, but the class-level risk applies.
Tolerance and Dependence
Tolerance develops almost immediately after a single dose through 5-HT₂A downregulation.[2] Community estimates place the tolerance half-life at approximately 3 days, with full reset within 7 days. These values are class-inferred; no substance-specific tolerance studies exist for 1P-ETH-LAD.
Cross-tolerance occurs with all classical serotonergic psychedelics — LSD, psilocybin, mescaline, DMT, and structural analogs — through the shared 5-HT₂A downregulation mechanism.[2]
Dependence liability is negligible. The LSD class is non-habit-forming and non-addictive. A population study of 130,152 participants found no association between psychedelic use and substance use disorders.[22] Rapid tolerance development physiologically discourages compulsive redosing, and no physical withdrawal has been documented for any LSD-class compound.
Drug Interactions
Serotonergic agents
Combining 1P-ETH-LAD with any serotonergic agent carries a risk of serotonin syndrome — a potentially life-threatening condition involving high body temperature, rapid heart rate, muscle rigidity, and altered mental status.
Tramadol (dangerous): tramadol combines opioid effects with serotonin reuptake inhibitor,[28] creating direct synergy with the 5-HT₂A agonism of ETH-LAD. Serotonin syndrome from tramadol–serotonergic agent combinations is well documented.[29] safety citation needed
MAOIs (recommended classification: dangerous): monoamine oxidase inhibitors block serotonin breakdown, dramatically potentiating psychedelic effects and increasing serotonin toxicity risk. This is a class-level contraindication for all 5-HT₂A agonists. safety citation needed
SSRIs/SNRIs: chronic use may blunt psychedelic effects through receptor downregulation. Acute co-administration could increase serotonin toxicity risk. The net effect depends on chronicity and the specific medication. safety citation needed
Lithium
Lithium (recommended classification: dangerous): the combination of lithium with LSD-class psychedelics carries well-documented risk of seizures. This is an absolute contraindication. safety citation needed
Cannabis
Cannabis (classified: unknown): community reports suggest cannabis potentiates psychedelic effects and may increase anxiety, paranoia, and challenging experiences. No controlled interaction data exist.
Contraindications
7 knownAll contraindications are class-inferred from the serotonergic psychedelic literature. No substance-specific data exist for 1P-ETH-LAD or ETH-LAD. inferred
Absolute contraindications:
- Personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar I with psychotic features): 5-HT₂A agonism may trigger or worsen psychotic episodes.
- Concurrent lithium use: seizure risk.
- Concurrent MAOI use: serotonin syndrome risk.
Relative contraindications:
- Anxiety disorders: increased risk of acute distress and panic attacks.
- Heart conditions: sympathomimetic effects may be clinically significant.
- Pregnancy: no reproductive toxicity data exist; class-level precaution applies.
- Concurrent serotonergic medications (SSRIs, SNRIs, tramadol, triptans): variable risk from blunted effects to serotonin syndrome.
Harm Reduction[edit]
Forms & Identification
The reagent and form data displayed above provide the first line of defense against substitution. For lysergamide blotters, the critical concern is compound identity — blotter paper can carry any substance, and lysergamides are indistinguishable by taste, smell, or appearance. Ehrlich reagent testing confirms the presence of an indole compound but cannot differentiate between lysergamides.
A positive Ehrlich result (purple color change) rules out the most dangerous substitutions — notably NBOMe compounds, which are active on blotter at similar quantities but carry serious overdose risk — without confirming the blotter contains 1P-ETH-LAD specifically. For liquid preparations, volumetric dosing is the only reliable approach, as the active range is measured in micrograms.
Guidelines
- Test the material. Use Ehrlich reagent at minimum. A purple reaction confirms an indole compound and rules out the most dangerous substitutions.
- Start with a low dose. Individual sensitivity to lysergamides varies. Begin at the lower end of the reported range and assess response before considering higher doses in future sessions.
- Plan for the duration. Effects last 6–12 hours with residual stimulation potentially extending beyond that. Clear the full day. Arrange transport in advance — do not drive.
- Arrange a sitter. A sober, trusted companion who can provide reassurance and practical support if the experience becomes difficult.
- Hydrate and eat beforehand. A light meal 2–3 hours before reduces nausea risk. Keep water accessible throughout.
- Avoid redosing. Tolerance develops within the first hour. Redosing does not reliably intensify the experience and extends the duration unpredictably.
- Prepare for intensity. Have a quiet, comfortable fallback space available. Changing environment — moving to a different room, going outside, changing music — can shift a difficult experience.
Set & Setting
Aftercare & integration. The days following a psychedelic experience are a period of heightened psychological openness. Allow time for rest and reflection before returning to demanding responsibilities. Journaling, conversation with trusted people, or creative expression can help process the experience.
Difficulty sleeping on the night of use is common due to residual stimulation and typically resolves within 24 hours. If disturbing perceptual changes, anxiety, or depersonalization persist beyond a few days, consult a mental health professional — ideally one with experience in psychedelic integration.
Psychedelic experiences are profoundly shaped by mental state (set) and physical environment (setting). A calm, familiar, private space with a trusted companion present provides the strongest foundation. Avoid using during periods of emotional distress, unresolved conflict, or significant life stress. First-time users and those unfamiliar with lysergamides should approach with particular care given the extended duration — plan for a full day with no obligations.
Recovery & Support
1P-ETH-LAD does not produce physical dependence or withdrawal. However, patterns of frequent psychedelic use — even without physiological compulsion — can reflect psychological avoidance or escapism. If psychedelic use is displacing responsibilities, relationships, or emotional processing, professional support may be warranted.
Resources for psychedelic-related concerns include the Fireside Project (psychedelic peer support line), MAPS integration resources, and local harm reduction organizations. For broader substance use concerns, SAMHSA's National Helpline (1-800-662-4357) provides free referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult psychedelic experiences are uncomfortable but not medically dangerous. Seek immediate help if the person expresses intent to harm themselves or others, loses all contact with reality and cannot be redirected, shows signs of seizure, or develops dangerously high body temperature.
Immediate steps:
- Stay with the person. Speak calmly and simply.
- Remove hazards from the environment — sharp objects, access to heights, vehicle keys.
- If conscious and cooperative, guide them to a quiet, low-stimulation space.
- If unconscious, place in the recovery position and call emergency services immediately.
- Call emergency services if there is any risk of self-harm, seizure, or loss of consciousness.
What to tell the dispatcher: Name the substance (1P-ETH-LAD or "an LSD-like research chemical"), estimated dose, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
The legal status of 1P-ETH-LAD varies by jurisdiction and is shaped by two factors: the scheduling of its active metabolite ETH-LAD, and the application of blanket novel psychoactive substance legislation to the prodrug form. Neither 1P-ETH-LAD nor ETH-LAD is controlled under any international treaty.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | ETH-LAD: Class A / Schedule 1 (Misuse of Drugs Act 1971). 1P-ETH-LAD: covered by Psychoactive Substances Act 2016. | ETH-LAD controlled from 7 January 2015 alongside ALD-52, AL-LAD, PRO-LAD, and LSZ.[30] 1P-ETH-LAD is not a named controlled substance but is illegal to produce, supply, or import under the Psychoactive Substances Act 2016.[31] |
| Germany | Controlled under NpSG (Neue-psychoaktive-Stoffe-Gesetz) | Effective 18 July 2019. Production, import with intent to market, administration to others, and trading are criminal offences. Possession is illegal but not penalized under NpSG. |
| United States | Not specifically scheduled | Neither ETH-LAD nor 1P-ETH-LAD is listed in the Controlled Substances Act. The Federal Analogue Act (21 U.S.C. § 813) may apply when intended for human consumption, treating the compound as Schedule I by analogy to LSD. Legal status remains ambiguous. |
| Canada | Not confirmed as controlled | No specific scheduling identified as of 2025. Status requires verification against current CDSA schedules. citation needed |
| Australia | Not confirmed | Specific scheduling under the Poisons Standard not verified. Analogous treatment to 1P-LSD is plausible but unconfirmed. citation needed |
| Japan | ETH-LAD under evaluation; 1P-ETH-LAD status unconfirmed | ETH-LAD detected in paper products 2014–2017.[6] 1P-LSD designated as controlled from April 2016. Current status of 1P-ETH-LAD not confirmed. |
Analog and prodrug considerations
The prodrug nature of 1P-ETH-LAD creates a distinctive legal dynamic. In jurisdictions where ETH-LAD is specifically controlled (such as the United Kingdom), the prodrug may fall under separate blanket legislation rather than the primary drug scheduling law. In jurisdictions that rely on structural analog laws (such as the United States Federal Analogue Act), legal exposure depends on whether 1P-ETH-LAD is deemed "substantially similar" to LSD and whether it is "intended for human consumption." This ambiguity has not been resolved by case law for 1P-ETH-LAD specifically.
Frequently asked questions
What is 1P-ETH-LAD?
1P-ETH-LAD is a semisynthetic lysergamide prodrug that converts in vivo to ETH-LAD, a serotonergic psychedelic active at microgram oral doses. First characterized in 2017, it has no clinical trial history; all human data derive from community surveys and user reports.
How long does 1P-ETH-LAD last?
Total duration by route of administration — Oral: 6 – 12 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 1P-ETH-LAD?
Psychedex publishes a dosage table for 1P-ETH-LAD on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 1P-ETH-LAD?
The highest-severity documented interactions for 1P-ETH-LAD: MAOIs (Lethal), Buspirone (Dangerous), DXM (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 1P-ETH-LAD addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 1P-ETH-LAD: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, psilocybin, mescaline, DMT, AL-LAD, 1P-LSD, 1B-LSD, 1CP-LSD. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcdBrandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, Nichols DE, Halberstadt AL (2017) Return of the lysergamides. Part III: Analytical characterization of ETH-LAD and 1P-ETH-LAD — Drug Testing and Analysis doi:10.1002/dta.2196
- [2] ^abcdWallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, et al. (2023) Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential — Nature Communications doi:10.1038/s41467-023-44016-1
- [3] ^abcNichols DE, Johnson MW, Nichols CD (2017) Psychedelics as Medicines: An Emerging New Paradigm — Clinical Pharmacology and Therapeutics doi:10.1002/cpt.557
- [4] ^abHoffman A, Nichols DE (1985) Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives — Journal of Medicinal Chemistry doi:10.1021/jm00147a022
- [5] ^abBrandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, et al. (2019) Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD) — Drug Testing and Analysis doi:10.1002/dta.2613
- [6] ^abTanaka R, Kawamura M, Hakamatsuka T, Kikura-Hanajiri R (2020) [Identification and Analysis of LSD Derivatives in Illegal Products as Paper Sheet] — Yakugaku Zasshi doi:10.1248/yakushi.19-00230
references
- [1]
- [2]
- [3] ^abcNichols DE, Johnson MW, Nichols CD (2017) Psychedelics as Medicines: An Emerging New Paradigm — Clinical Pharmacology and Therapeutics doi:10.1002/cpt.557
- [4] ^abcHoffman A, Nichols DE (1985) Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives — Journal of Medicinal Chemistry doi:10.1021/jm00147a022
- [5] ^abBrandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, et al. (2019) Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD) — Drug Testing and Analysis doi:10.1002/dta.2613
- [6] ^abTanaka R, Kawamura M, Hakamatsuka T, Kikura-Hanajiri R (2020) [Identification and Analysis of LSD Derivatives in Illegal Products as Paper Sheet] — Yakugaku Zasshi doi:10.1248/yakushi.19-00230